Skip to main content
SpringerLink
Log in

Nucleic Acid Aptamers for Cardiovascular Therapeutics

  • Chapter
RNA Technologies in Cardiovascular Medicine and Research

  • 371 Accesses

Abstract

Nucleic acid aptamers can fold into a multitude three-dimensional structures allowing them to bind to almost any small molecule, nucleic acid or protein target with high specificity and affinity. Aptamers can be generated in a controlled and entirely in vitro process known as SELEX. Advances in aptamer technology have made possible the application of this therapeutic modality to many therapeutic areas including cardiovascular indications. To that end, aptamers have been generated to coagulants, adhesion, and angiogenic targets leading to the pre-clinical and clinical development of numerous aptamer drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Bock LC, Griffin LC, Latham JA et al (1995) Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355:564–566

    Article  Google Scholar 

  • Burmeister PE, Wang C, Killough J R et al (2006) 2B-Deoxy purine, 2–O-methyl pyrimidine (dRmY) aptamers as candidate therapeutics. Oligonucleotides 16(4):337–351

    Article  PubMed  CAS  Google Scholar 

  • Boncler MA, Koziolkiewicz M, Watala C (2001) Aptamer inhibits degradation of platelet proteolytically activatable receptor, PAR-1, by thrombin. Thromb Res 104:215–222

    Article  PubMed  CAS  Google Scholar 

  • Chyu K-Y, Shah PK (2007) Choking off plaque neovascularity: a promising atheroprotective strategy or a double-edged sword? Arterioscl Thromb Vasc Biol 27:993–995

    Article  PubMed  CAS  Google Scholar 

  • Cload ST, McCauley TG, Keefe AD et al (2006) Properties of therapeutic aptamers. In: Klussman S (ed) The aptamer handbook. Wiley, Weinheim, pp 363–416

    Chapter  Google Scholar 

  • Dougan H, Lyster DM, Vo CV et al (2000). Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. Nucl Med Biol 27:289–297

    Article  PubMed  CAS  Google Scholar 

  • Doyle B, Caplice N (2007) Plaque neovascularization and antiangiogenic therapy for atherosclerosis. J Am Coll Cardiol 49:2102–2104

    Article  Google Scholar 

  • Dyke CK, Steinhubl SR, Kleiman NS et al (2006) First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology. A Phase Ia pharmacodynamic evaluation of a drug-antidote paior for the controlled regulation of factor IXa activity. Circulation 114:2490–2497

    Article  PubMed  CAS  Google Scholar 

  • Eyetech Study Group (2003). Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 110:979–986

    Article  Google Scholar 

  • Furie B, Furie B (2007) In vivo thrombosis. J Thromb Haemost Suppl 1:12–17

    Article  Google Scholar 

  • Gilbert JC, DeFeo-Fraulini T, Hutabarat RM et al (2007) Pharmacokinetis, pharmacodynamics, and safety of an anti-von Willebrand factor therapeutic aptamer, ARC1779, in healthy volunteers. Circulation 116:2678–2686

    Article  PubMed  CAS  Google Scholar 

  • Green LS, Jellinek D, Bell C et al (1995) Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol 2:683–695

    Article  PubMed  CAS  Google Scholar 

  • Griffin LC, Tidmarsh GF, Bock LC et al (1993) In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits. Blood 81:3271–3276

    PubMed  CAS  Google Scholar 

  • Healy JM, Lewis SD, Kurz M et al (2004) Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm Res 21:2234–2246

    Article  PubMed  CAS  Google Scholar 

  • Hennan JK, Swillo RE, Morgan GA et al (2006) Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis. Thromb Haemost 95:469–475

    PubMed  CAS  Google Scholar 

  • Huang J, Moore J, Soffer S et al (2001) Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. J Pediatr Surg 36:357–361

    Article  PubMed  CAS  Google Scholar 

  • Hutabarat R, Horvath C, Funk WD (2007) Discovery of a potent, direct thrombin inhibiting aptamer, J Thromb Haemost 5(Suppl 2):P-S-067

    Google Scholar 

  • Italiano JE, Richardson JL, Patel-Hett S Et al (2008) Angiogenesis is regulated by a novel mechanism: Pro- and anti-angiogenic proteins are organized into separate platelet a-granules and differentially released. Blood 111(3):1227–1233 (published ahead of print On-Line October 25, 2007)

    Article  PubMed  CAS  Google Scholar 

  • Jenison RD, Jennings SD, Walker DW et al (1998) Oligonucleotide inhibitors of P-selectin-dependent neutrophil-platelet adhesion. Antisense Nucleic Acid Drug Dev 8:265–279

    PubMed  CAS  Google Scholar 

  • Kahlon R, Shapero J, Gotlieb AI (1992) Angiogenesis in atherosclerosis. Can J Cardiol 8:60–64

    PubMed  CAS  Google Scholar 

  • Kolodgie FD, Narulo J, Yuan C et al (2007) Elimination of neoangiogenesis for plaque stabilization: Is there a role for local drug therapy? J Am Coll Cardiol 49:2093–2101

    Article  PubMed  CAS  Google Scholar 

  • Lagassé HAD, Merlino PG, Marsh HN et al (2007) Discovery and characterization of a potent neutralizing anti-VWF A1 domain specific aptamer. J Thromb Haemost 5(Suppl 2):P-S-665

    Google Scholar 

  • Leppanen O, Janjic N, Carlsson M-A et al (2000) Intimal hyperpasia recurs after removal of PDGF-AB and BB inhibition by the rat carotid artery injury model. Arterioscl Thromb Vasc Biol 20:89–95

    Google Scholar 

  • Li W-X, Kaplan AV, Grant GW et al (1994) A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation. Blood 83:677–682

    PubMed  CAS  Google Scholar 

  • Michel JB, Thaunat O, Houard X, et al. (2007) Topological determinants and consequences of adventitial responses to arterial wall injury. Arterioscler Thromb Vasc Biol 27:1259–1268

    Article  PubMed  CAS  Google Scholar 

  • Ng EWM, Adamis AP (2006) Anti-VEGF aptamer (pegaptanib) yherapy for ocular vascular diseases. Oligonucleotide thrapeutics: First Annual Meeting of the Oligonucleotide Therapeutics Society. Ann NY Acad Sci 1082:151–171

    Article  PubMed  CAS  Google Scholar 

  • Nimjes SM, Keys JR, Pitoc GA et al (2006) A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. Mol Ther 24:408–415

    Article  Google Scholar 

  • Nishimura JI, Burnette AD, Oney S et al (2007) Blood 110(11): Abstract 147

    Google Scholar 

  • Oney S, Nimjee SM, Layzer J et al (2007) Antidote-Controlled Platelet inhibition targeting von Willebrand factor with aptamers. Oligonucleotides 17:265–274

    Article  PubMed  CAS  Google Scholar 

  • Ostendorf T, Kunter U, Grone HJ et al (2001). Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 12:909–918

    PubMed  CAS  Google Scholar 

  • Paborsky LR, McCurdy SN, Griffin LC et al (1993) The single stranded DNA aptamer-binding site of human thrombin. J Biol Chem 268:20808–20811

    PubMed  CAS  Google Scholar 

  • Petrovan PJ, Kaplan CD, Reisfeld RA et al (2007) DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice. Arterioscl Thromb Vasc Biol 27:1095–1100

    Article  PubMed  CAS  Google Scholar 

  • Rottman RB, Gilbert M, Marsh HN et al (2007) An anti-Von Willebrand’s factor A1 domain aptamer inhibits arterial thrombosis induced by electrical injury in cynomolgus macaques. J Thromb Haemost 5(Suppl 2):P-S-664

    Google Scholar 

  • Rusconi CP, Yeh A, Lyerly HK et al (2000) Blocking the initiation of coagulation by RNA aptamers to Factor VIIa. Thromb Haemost 84:841–848

    PubMed  CAS  Google Scholar 

  • Rusconi CP, Roberts JD, Pitoc GA et al (2004a) Antidote-mediated control of an anticoagulant aptamer in vivo. Nat Biotechnol 22:1423–1428

    Article  PubMed  CAS  Google Scholar 

  • Rusconi CP, Scardino E, Layzer J et al (2004b) RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 419:90–94

    Article  Google Scholar 

  • Sarraf-Yazdi S, Mi J, Moeller BJ et al (2007) Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin-2 specific RNA aptamer. J Surg Res (published on-line Oct 22 2007)

    Google Scholar 

  • Sennino B, Falcon BL, McCauley D et al (2007) Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 67:7358–7367

    Article  PubMed  CAS  Google Scholar 

  • Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505–510

    Article  PubMed  CAS  Google Scholar 

  • Wagner-Whyte J, Khuri SF, Preiss JR et al (2007) Discovery of a potent, direct thrombin inhibiting aptamer. J Thromb Haemost 5(Suppl 2):P-S-067

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Archemix Corp., 300 Third St. 2nd Floor, Cambridge, MA, 02139, USA

    P. S. Pendergrast, K. M. Thompson & R. G. Schaub

Authors
  1. P. S. Pendergrast
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. M. Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. G. Schaub
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. S. Pendergrast .

Editor information

Editors and Affiliations

  1. Institute for Chemistry/Biochemistry, Free University of Berlin, Thielallee 63, 14195, Berlin, Germany

    Volker A. Erdmann

  2. Clinic for Cardiology and Pneumology Campus Benjamin Franklin, Charite University Medicine Berlin, Hindenburgdamm 30, 12200, Berlin, Germany

    Wolfgang Poller

  3. Institute of Bioorganic Chemistry of the Polish Academy of Sciences, Noskowskiego 12, 61-704, Poznan, Poland

    Jan Barciszewski

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Pendergrast, P.S., Thompson, K.M., Schaub, R.G. (2008). Nucleic Acid Aptamers for Cardiovascular Therapeutics. In: Erdmann, V.A., Poller, W., Barciszewski, J. (eds) RNA Technologies in Cardiovascular Medicine and Research. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-78709-9_14

Download citation

Publish with us

Policies and ethics

Search

Navigation